Parkinson Disease

Poor higher order vision at baseline was associated with worsening cognition and increased probability of death, dementia, or frailty over 3 years.

Over 48 weeks of treatment, ALXN1480 was found to be generally well-tolerated, with improvements seen in Clinical Global Impression-Improvement scores and UWDRS Parts II and III.

The medical director of the Center for Neurological Disorders at the University of Toledo discussed positive phase 3 findings assessing P2B001, and how the agent would potentially fit in the Parkinson treatment landscape. [WATCH TIME: 4 minutes]

The chief medical officer and cofounder of CND Life Sciences, who served as principal investigator of the study, offered insight into the Syn-ONe Test's clinical utility.

The pump, attached to a wearable retainer, continuously delivers the liquid medication with little to no adverse effects.

CND Life Sciences’ α-synuclein skin biopsy test showed sensitivity rates ranging from 92.7% to 100% across a number of assessed and clinically confirmed synucleinopathies, including Parkinson disease and dementia with Lewy bodies, among others.

Compared with immediate-release levodopa/carbidopa, NeuroDerm’s 24-hour subcutaneous liquid infusion improved ON time without dyskinesia and with nontroublesome dyskinesia.

The majority of treatment-emergent adverse events from IPX203 were mild or moderate in nature, and occurred within the first 90 days of treatment.

Andrew Siderowf, MD, director of the Parkinson disease and movement center at the University of Pennsylvania, talked about available therapeutics and potential future therapies in research for Parkinson disease.

Despite years of use of gold-standard therapy levodopa, therapeutic development in Parkinson disease has advanced rapidly and expanded to numerous novel pathways and targets.

The director of the Memory & Cognitive Disorders Clinic at Hoag Neuroscience Institute provided detail on an educational course that examined medication management for Parkinson disease psychosis.

As therapeutic development has advanced in Parkinson disease management, the introduction of on-demand options have extended ON time for patients and altered the paradigm of care.

Psychosis is estimated to affect more than half of patients with Parkinson disease, and there is a growing need for improved management and therapeutic development.

The holy grail of neurodegenerative disorders would be to alter or halt the progression of the disease. For years, the discussion has swirled around stem cells and gene therapy, and they remain potential options for the future.

Findings from a recent published study observed lower quality of life in Black, Hispanic, and Asian patients with Parkinson disease compared with White patients.

New research confirms a key disease pathology identified through examining spinal fluid in patients with Parkinson disease.

The neurosurgeon at Marcus Neuroscience Institute, Baptist Health, provided perspective on the advances of DBS and other invasive procedures for patients with degenerative disorders. [WATCH TIME: 4 minutes]

Positive phase 2 data on CVN424, NETSseq platforms, and CVN417, a novel treatment for Parkinson disease, were presented at AD/PD 2023 International Conference.

New data demonstrated the potential of a new class of oral, small molecule inhibitors that target the fleeting intermediates at the core of neurodegeneration in Parkinson disease.

Statistically significant improvements in several quantitative test measures of episodic memory, attentiveness, and depressive emotional bias were observed in patients treated with clenbuterol and nadolol.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Parkinson disease (PD).

In honor of Parkinson Disease Awareness Month, Hubert Fernandez, MD, director of the Center for Neurological Restoration at Cleveland Clinic, provided perspective on the advances in the care for the neurodegenerative disorder.

Despite a pause in the trial due to the COVID-19 pandemic, patients who opted to continue treatment into the open-label extension demonstrated significant improvements in Parkinson disease dementia symptoms for up to 48 weeks.

Over a 12-week treatment period, patients with Parkinson disease on light therapy demonstrated statistically significant improvements of 58% and 40% in lower and upper limb coordination and movement.

The vice president of Health Economic and Outcomes Research at Acadia Pharmaceuticals provided perspective on the negative effects seen from quetiapine and how the knowledge of pimavanserin has improved since approval. [WATCH TIME: 5 minutes]